Skip to main content
. 2020 Dec 7;7:538815. doi: 10.3389/fmed.2020.538815

Table 1.

Descriptive statistics of demographic and tumor characteristics (n = 105).

Total (n = 105) TOP (n = 67) COP (n = 38) Difference in means (95% CI)
Age (yrs), mean (SD), range 35.0 (5.3), 17–45 34.2 (5.1), 17–44 32.3 (5.6), 23–45 1.8 (−0.2 to 4.0)
Gravida, mean (SD), range 3.6 (1.7), 1–9 3.8 (1.6), 1–8 3.2 (1.9), 1–9 0.6 (−0.4 to 1.3)
Para, mean (SD), range 1.3 (1.2), 0–7 1.4 (1.0), 0–5 1.3 (1.5), 0–7 0.1 (−0.3 to 0.6)
GA at diagnosis (wks), mean (SD), range 20.0 (11.1), 5–41 14.8 (7.7), 5–31 30.8 (8.5), 6–41 −16.0 (−19.3 to −12.8)*
Method of disease detection, n (%)
Bleeding 90 (85.7) 57 (85.1) 33 (86.8) −1.8 (−14.6 to 13.9)
Physical examination 8 (7.6) 4 (6.0) 4 (10.5) −4.6 (−18.6 to 6.0)
Abnormal cervical cancer screening 7 (6.7) 6 (8.9) 1 (2.6) 6.3 (−5.6 to 15.8)
FIGO Stage, n (%)
IA 7 (6.7) 3 (4.5) 4 (10.5) −6.1 (−20.0 to 4.1)
IB1 30 (28.6) 19 (28.4) 11 (28.9) −0.6 (−19.0 to 16.2)
IB2 33 (31.4) 26 (38.8) 7 (18.4) 20.4 (1.9 to 35.5)*
II 28 (26.6) 17 (25.4) 11 (28.9) −3.6 (−21.7 to 13.1)
III–IV 7 (6.7) 2 (3.0) 5 (13.2) −10.2 (−24.5 to 0.2)
Pathological type, n (%)
Squamous cell carcinoma 83 (79.1) 53 (79.1) 30 (78.9) 0.16 (−14.8 to 17.4)
Adenocarcinoma 16 (15.2) 10 (14.9) 6 (15.8) −0.9 (−16.9 to 12.5)
Other type 6 (5.7) 4 (6.0) 2 (5.3) 0.7 (−11.8 to 9.9)
Tumor size, n (%)
≤4 cm 46 (43.8) 30 (44.8) 16 (42.1) 2.7 (−16.7 to 21.2)
>4 cm 59 (56.2) 37 (55.2) 22 (57.9) −2.7 (−21.2 to 16.7)

TOP, termination of pregnancy; COP, continuation of pregnancy; GA, gestational age; yrs, years; wks, weeks.

*

P < 0.01.

Three cases of small cell carcinoma, one case of poorly differentiated carcinoma, one case of cervical sarcoma, and one case of neuroendocrine carcinoma.